Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Analysis of Reportable Segments
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
The cash flow profile exhibits a period of volatility between 2021 and 2023, followed by a sustained recovery phase. While both net cash provided by operating activities and free cash flow to the firm (FCFF) experienced a notable contraction in the 2023 fiscal year, subsequent periods indicate a consistent return to growth, with figures approaching 2022 levels by 2026.
- Operating Cash Flow Trends
- Net cash provided by operating activities peaked in 2022 at 7,346 million US$, representing a significant increase from the 6,240 million US$ recorded in 2021. A sharp decline occurred in 2023, where cash flow dropped to 6,039 million US$, before entering a steady growth phase that reaches 7,330 million US$ by 2026.
- Free Cash Flow to the Firm (FCFF) Performance
- FCFF closely mirrors the trajectory of operating cash flow, reaching a high of 6,473 million US$ in 2022 before falling to a period low of 5,007 million US$ in 2023. From 2024 through 2026, FCFF demonstrates a moderate recovery, stabilizing and eventually reaching 6,036 million US$, although it remains below the 2022 peak.
- Cash Conversion and Capital Expenditure Patterns
- A consistent gap is observed between operating cash flow and FCFF, reflecting the impact of capital expenditures. Analysis of this gap indicates a shift in capital allocation; between 2024 and 2026, operating cash flow grew by approximately 533 million US$, while FCFF grew by only 203 million US$. This divergence suggests an increasing proportion of operating cash is being directed toward capital investments in the latter part of the period.
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
2 2026 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= × =
The financial trajectory of net interest payments and the effective income tax rate exhibits significant volatility between April 2021 and April 2026, characterized by a distinct U-shaped trend in cash outflows and erratic tax rate fluctuations.
- Net Interest Cash Outflow Trends
- Cash paid for interest, net of tax, decreased steadily from 542 million USD in 2021 to a period low of 427 million USD in 2023. This downward trend was followed by a substantial increase in 2024, where payments rose to 633 million USD. The expenditure remained relatively plateaued in 2025 at 636 million USD before experiencing a slight contraction to 610 million USD in 2026.
- Effective Income Tax Rate (EITR) Analysis
- The EITR demonstrated high variability over the analyzed timeframe. After starting at 6.80% in 2021 and 8.30% in 2022, the rate spiked to a peak of 29.50% in 2023. A subsequent decline occurred over the next two years, reaching 16.60% in 2025, followed by a modest recovery to 21.20% in 2026.
- Correlation Between Tax Rates and Net Interest Costs
- An inverse relationship is observed between the EITR and net interest payments during the 2023 fiscal year. The peak tax rate of 29.50% coincides with the lowest net interest payment of 427 million USD, indicating that the increased tax shield significantly reduced the net cash impact of interest expenses. Conversely, as the tax rate normalized in 2024 and 2025, the net cash paid for interest reached its highest levels in the series.
Enterprise Value to FCFF Ratio, Current
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | |
| Free cash flow to the firm (FCFF) | |
| Valuation Ratio | |
| EV/FCFF | |
| Benchmarks | |
| EV/FCFF, Competitors1 | |
| Abbott Laboratories | |
| Elevance Health Inc. | |
| Intuitive Surgical Inc. | |
| UnitedHealth Group Inc. | |
| EV/FCFF, Sector | |
| Health Care Equipment & Services | |
| EV/FCFF, Industry | |
| Health Care | |
Based on: 10-K (reporting date: 2026-04-24).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Enterprise value (EV)1 | |||||||
| Free cash flow to the firm (FCFF)2 | |||||||
| Valuation Ratio | |||||||
| EV/FCFF3 | |||||||
| Benchmarks | |||||||
| EV/FCFF, Competitors4 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
| EV/FCFF, Sector | |||||||
| Health Care Equipment & Services | |||||||
| EV/FCFF, Industry | |||||||
| Health Care | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
3 2026 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =
4 Click competitor name to see calculations.
The valuation multiple based on Enterprise Value to Free Cash Flow to the Firm (EV/FCFF) exhibits a significant initial contraction followed by a period of relative stabilization. A peak ratio of 33.84 in 2021 decreased sharply to 20.32 by 2022, indicating a substantial correction in market valuation relative to the entity's cash flow generation capacity.
- Enterprise Value Dynamics
- A notable reduction in Enterprise Value occurred between April 2021 and April 2022, with the value falling from 183,640 million to 131,529 million. Following this decline, the value entered a period of consolidation, fluctuating within a range of approximately 120,000 million to 130,000 million through the 2026 projection period.
- Free Cash Flow to the Firm (FCFF) Trends
- FCFF demonstrated moderate volatility, peaking at 6,473 million in 2022 before experiencing a trough of 5,007 million in 2023. A recovery trend is observed from 2024 onward, with cash flows stabilizing and eventually reaching a projected 6,036 million by 2026, suggesting a consistent underlying ability to generate cash.
- EV/FCFF Ratio Interpretation
- The ratio underwent a sharp decline of approximately 40% between 2021 and 2022. While a temporary increase to 26.54 was recorded in 2023, the multiple has since converged toward a baseline of approximately 20x. This trend indicates that the market valuation has transitioned from a highly optimistic premium in 2021 to a more conservative and stable alignment with actual cash flow performance.